Sucampo Pharmaceuticals, Inc. Class A(NASDAQ : SCMP)
Volume Open Day's Low Day's High 52 Wk Low 52 Wk High Bid Ask EPS PE Ratio Shares Market Cap Dividend Ex-Div Date Yield
Yes, 3x ETFs are Awesome!
Like TNA, UGAZ, UWTI, NUGT? We do too...Join Up!
Loading SCMP News...
Health Technology » Pharmaceuticals Major
|JNJ||Johnson & Johnson||-0.29%||125.53||0.6%||$974.28m|
|MRK||Merck & Co., Inc.||-0.14%||63.19||0.6%||$590.05m|
|BMY||Bristol-Myers Squibb Company||0.25%||55.91||2.8%||$587.15m|
|LLY||Eli Lilly and Company||-0.26%||84.20||1.1%||$313.42m|
|NVS||Novartis AG Sponsored ADR||-0.08%||74.37||0.2%||$215.25m|
|AZN||AstraZeneca PLC Sponsored ADR||0.00%||31.30||1.1%||$155.11m|
|GSK||GlaxoSmithKline plc Sponsored ADR||0.01%||42.32||0.3%||$111.26m|
|NVO||Novo Nordisk A/S Sponsored ADR Class B||1.21%||33.55||0.1%||$70.19m|
|SNY||Sanofi Sponsored ADR||0.25%||44.62||0.2%||$62.32m|
|LCI||Lannett Company, Inc.||1.18%||21.45||36.7%||$15.34m|
|SCMP||Sucampo Pharmaceuticals, Inc. Class A||-1.40%||10.60||15.6%||$10.22m|
|AKTX||Akari Therapeutics Plc Sponsored ADR||0.85%||6.50||0.1%||$0.13m|
|EPIX||ESSA Pharma Inc||-6.01%||2.95||0.0%||$0.03m|
Sucampo Pharmaceuticals, Inc. is a biopharmaceutical company which engages in research, discovery, development and commercialization of proprietary drugs in the Americas, Europe and Asia. It is developing prostones, which are ion channel activators, to treat gastrointestinal, ophthalmic and oncology-based inflammatory disorders, as well as other therapeutic applications of drug technologies. The company's product pipeline includes AMITIZA for the treatment of chronic idiopathic constipation in adults; irritable bowel syndrome with constipation in adult women; opioid-induced constipation in patients with chronic non-cancer pain; chronic constipation; and pediatric functional constipation. Its product pipeline also consists of Unoprostone Isopropyl, which is in Phase III trial for the treatment of retinitis pigmentosa and in pre-clinical stage for the treatment of geographic atrophy; and Cobiprostone that has completed Phase Ib trial for the treatment of oral mucositis, as well as in Phase II trial for the treatment of non-erosive reflux diseases. Sucampo Pharmaceuticals was founded by Dr. Ryuji Ueno and Dr. Sachiko Kuno on December 5, 1996 and is headquartered in Bethesda, MD.